Last reviewed · How we verify
Piritetrate — Competitive Intelligence Brief
phase 2
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Piritetrate (LIRANAFTATE). Piritetrate works by binding to a specific target, although the exact mechanism is currently unknown.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Piritetrate TARGET | LIRANAFTATE | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Piritetrate CI watch — RSS
- Piritetrate CI watch — Atom
- Piritetrate CI watch — JSON
- Piritetrate alone — RSS
Cite this brief
Drug Landscape (2026). Piritetrate — Competitive Intelligence Brief. https://druglandscape.com/ci/liranaftate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing